Phase 4
Completed N=178
Intrafetal Digoxin as an Adjuvant for Dilation and Evacuation at 20 to 24 Weeks' Gestation
Abortion
Source: ClinicalTrials.gov NCT03136068 ↗
Enrolled (actual)
178
Serious AEs
0.6%
Results posted
Oct 2019
Primary outcomePrimary: Procedure Duration — 6.8; 7.2 minutes
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This is a research study to measure the effect of digoxin injection on Dilation and Evacuation (D&E) procedure duration. Digoxin is the most commonly used feticidal agent among family planning subspecialists, and is commonly used for a variety of reasons including provider preference, patient preference, and concerns over legal status of later D&E procedures. There have been several studies on digoxin administration, adverse effects, and impact on the D&E procedure, but doctors want to clarify how digoxin effects D&E procedure time, if at all.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Procedure Duration |
6.8; 7.2 | — |
| SECONDARY Total Procedure Duration |
9.7; 8.3 | — |
| SECONDARY Measured Blood Loss |
417; 363 | — |
| SECONDARY Number of Patients With Reported Fetal Death Prior to Procedure |
68; 6 | — |
| SECONDARY Complications |
8; 4 | — |
Eligibility Criteria
Inclusion Criteria
- 20 weeks 0 days-24 weeks 0 days gestation
- English or Spanish speaking
- 18 years or older
Exclusion Criteria
- Under 18
- Contraindications to digoxin
Data sourced from ClinicalTrials.gov (NCT03136068). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.